Also known as: KTE-X19
Tecartus (brexucabtagene autoleucel) is a CD19-directed genetically modified autologous T-cell immunotherapy used in relapsed or refractory mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia in adults. FDA product records list ongoing regulatory updates through April 2026.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
New antibody-based approaches demonstrate clinical benefits across multiple cancer types, including improved survival in triple-negative breast cancer, enhanced tumor detection via PET imaging, and activity in relapsed mantle cell lymphoma.
CAR T-cell therapy market advances with AI-driven manufacturing improvements and over 250 companies developing 500+ drug candidates, including breakthrough solid tumor treatments and GPC3-targeted therapies for hepatocellular carcinoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06144606 |
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) |
RECRUITING | PHASE2 |
| NCT03642626 |
MT2017-45: CAR-T Cell Therapy for Heme Malignancies |
ACTIVE_NOT_RECRUITING | PHASE2 |
